FASST banner Inventiva website FASST home page
Presentation
of the trial
A randomized, double-blind, placebo-controlled, multicentre proof-of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis

To learn more about this study, you may contact the study research staff:
Mari Carmen DELATTE
mari-carmen.delatte@inventivapharma.com

Purpose (presentation of the treatment: IVA337)

IVA 337 is a new chemical entity (4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl]butanoic acid) that activates all three Peroxisome Proliferator-Activated Receptors (PPAR) isotypes PPARα, PPARδ and PPARγ.

The PPARs are ligand-activated transcription factors belonging to the nuclear hormone receptor family that regulate a range of physiological activities (metabolic activities, vascular function, anti-inflammatory, anti fibrotic). PPAR activation inhibits the fibrogenic process at multiple entry points:
  • Inflammation, growth factors, cytokines & chemokines
  • Fibroblast proliferation & differentiation
  • Myofibroblast proliferation, survival & migration
  • Extracellular matrix deposition
  • Fibrosis
IVA337 was designed to produce moderate panPPAR activation, with partial activation of PPARγ. It has demonstrated consistent anti-fibrotic activity in vitro and in vivo across multiple models and several organs: skin, kidney, lung and liver. In Phase I trials, the clinical program involved 100 volunteers treated. 47 patients were also treated in a 4-week phase IIa in Type 2 Diabetes Mellitus (T2DM).


more/less

contact us | © Inventiva 2016